Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

Elihu H. Estey, Francis J. Giles, Miloslav Beran, Susan O'Brien, Sherry A. Pierce, Stefan H. Faderl, Jorge E. Cortes, Hagop M. Kantarjian

Research output: Contribution to journalArticle

Abstract

We administered gemtuzumab ozogamycin ("mylotarg"; 9 mg/m 2 day 1 or 5) and all-trans retinoic acid (ATRA) to 19 patients with untreated acute promyelocytic leukemia (APL). There were 3 patients who also received idarubicin because of a white blood cell (WBC) count of more than 30 000/μL. In complete remission (CR), patients were to receive 8 courses of mylotarg (9 mg/m 2 every 4 to 5 weeks) and ATRA; idarubicin was added only for persistent or recurrent polymerase chain reaction (PCR) positivity. The CR rate was 16/19 (84%). All 12 patients tested to date were PCR-negative 2 to 4 months from CR date; none of the 7 patients evaluated subsequently have reverted to PCR positivity (median follow-up in CR was 5 months, up to 14 months). Mylotarg was well tolerated. A median of 5 post-CR courses have been given to date with 3 patients having currently received 8 post-CR courses, and 4 patients receiving 7 post-CR courses. Mylotarg appears active in APL, and repeated administration is feasible.

Original languageEnglish (US)
Pages (from-to)4222-4224
Number of pages3
JournalBlood
Volume99
Issue number11
DOIs
StatePublished - Jun 1 2002

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Polymerase chain reaction
Idarubicin
Polymerase Chain Reaction
Blood
Cells
gemtuzumab
Leukocyte Count

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Estey, E. H., Giles, F. J., Beran, M., O'Brien, S., Pierce, S. A., Faderl, S. H., ... Kantarjian, H. M. (2002). Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood, 99(11), 4222-4224. https://doi.org/10.1182/blood-2001-12-0174

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. / Estey, Elihu H.; Giles, Francis J.; Beran, Miloslav; O'Brien, Susan; Pierce, Sherry A.; Faderl, Stefan H.; Cortes, Jorge E.; Kantarjian, Hagop M.

In: Blood, Vol. 99, No. 11, 01.06.2002, p. 4222-4224.

Research output: Contribution to journalArticle

Estey, EH, Giles, FJ, Beran, M, O'Brien, S, Pierce, SA, Faderl, SH, Cortes, JE & Kantarjian, HM 2002, 'Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia', Blood, vol. 99, no. 11, pp. 4222-4224. https://doi.org/10.1182/blood-2001-12-0174
Estey, Elihu H. ; Giles, Francis J. ; Beran, Miloslav ; O'Brien, Susan ; Pierce, Sherry A. ; Faderl, Stefan H. ; Cortes, Jorge E. ; Kantarjian, Hagop M. / Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. In: Blood. 2002 ; Vol. 99, No. 11. pp. 4222-4224.
@article{576c35f4902c481c85b29379ff2864e6,
title = "Experience with gemtuzumab ozogamycin ({"}mylotarg{"}) and all-trans retinoic acid in untreated acute promyelocytic leukemia",
abstract = "We administered gemtuzumab ozogamycin ({"}mylotarg{"}; 9 mg/m 2 day 1 or 5) and all-trans retinoic acid (ATRA) to 19 patients with untreated acute promyelocytic leukemia (APL). There were 3 patients who also received idarubicin because of a white blood cell (WBC) count of more than 30 000/μL. In complete remission (CR), patients were to receive 8 courses of mylotarg (9 mg/m 2 every 4 to 5 weeks) and ATRA; idarubicin was added only for persistent or recurrent polymerase chain reaction (PCR) positivity. The CR rate was 16/19 (84{\%}). All 12 patients tested to date were PCR-negative 2 to 4 months from CR date; none of the 7 patients evaluated subsequently have reverted to PCR positivity (median follow-up in CR was 5 months, up to 14 months). Mylotarg was well tolerated. A median of 5 post-CR courses have been given to date with 3 patients having currently received 8 post-CR courses, and 4 patients receiving 7 post-CR courses. Mylotarg appears active in APL, and repeated administration is feasible.",
author = "Estey, {Elihu H.} and Giles, {Francis J.} and Miloslav Beran and Susan O'Brien and Pierce, {Sherry A.} and Faderl, {Stefan H.} and Cortes, {Jorge E.} and Kantarjian, {Hagop M.}",
year = "2002",
month = "6",
day = "1",
doi = "10.1182/blood-2001-12-0174",
language = "English (US)",
volume = "99",
pages = "4222--4224",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

AU - Estey, Elihu H.

AU - Giles, Francis J.

AU - Beran, Miloslav

AU - O'Brien, Susan

AU - Pierce, Sherry A.

AU - Faderl, Stefan H.

AU - Cortes, Jorge E.

AU - Kantarjian, Hagop M.

PY - 2002/6/1

Y1 - 2002/6/1

N2 - We administered gemtuzumab ozogamycin ("mylotarg"; 9 mg/m 2 day 1 or 5) and all-trans retinoic acid (ATRA) to 19 patients with untreated acute promyelocytic leukemia (APL). There were 3 patients who also received idarubicin because of a white blood cell (WBC) count of more than 30 000/μL. In complete remission (CR), patients were to receive 8 courses of mylotarg (9 mg/m 2 every 4 to 5 weeks) and ATRA; idarubicin was added only for persistent or recurrent polymerase chain reaction (PCR) positivity. The CR rate was 16/19 (84%). All 12 patients tested to date were PCR-negative 2 to 4 months from CR date; none of the 7 patients evaluated subsequently have reverted to PCR positivity (median follow-up in CR was 5 months, up to 14 months). Mylotarg was well tolerated. A median of 5 post-CR courses have been given to date with 3 patients having currently received 8 post-CR courses, and 4 patients receiving 7 post-CR courses. Mylotarg appears active in APL, and repeated administration is feasible.

AB - We administered gemtuzumab ozogamycin ("mylotarg"; 9 mg/m 2 day 1 or 5) and all-trans retinoic acid (ATRA) to 19 patients with untreated acute promyelocytic leukemia (APL). There were 3 patients who also received idarubicin because of a white blood cell (WBC) count of more than 30 000/μL. In complete remission (CR), patients were to receive 8 courses of mylotarg (9 mg/m 2 every 4 to 5 weeks) and ATRA; idarubicin was added only for persistent or recurrent polymerase chain reaction (PCR) positivity. The CR rate was 16/19 (84%). All 12 patients tested to date were PCR-negative 2 to 4 months from CR date; none of the 7 patients evaluated subsequently have reverted to PCR positivity (median follow-up in CR was 5 months, up to 14 months). Mylotarg was well tolerated. A median of 5 post-CR courses have been given to date with 3 patients having currently received 8 post-CR courses, and 4 patients receiving 7 post-CR courses. Mylotarg appears active in APL, and repeated administration is feasible.

UR - http://www.scopus.com/inward/record.url?scp=0036625070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036625070&partnerID=8YFLogxK

U2 - 10.1182/blood-2001-12-0174

DO - 10.1182/blood-2001-12-0174

M3 - Article

C2 - 12010830

AN - SCOPUS:0036625070

VL - 99

SP - 4222

EP - 4224

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -